Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001989989 | SCV002232485 | pathogenic | Hereditary nonpolyposis colorectal neoplasms | 2022-03-12 | criteria provided, single submitter | clinical testing | This variant has not been reported in the literature in individuals affected with MSH6-related conditions. For these reasons, this variant has been classified as Pathogenic. This variant is not present in population databases (gnomAD no frequency). This sequence change creates a premature translational stop signal (p.Lys301Argfs*4) in the MSH6 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in MSH6 are known to be pathogenic (PMID: 18269114, 24362816). |
Ambry Genetics | RCV002370601 | SCV002683490 | pathogenic | Hereditary cancer-predisposing syndrome | 2021-05-14 | criteria provided, single submitter | clinical testing | The c.900delG pathogenic mutation, located in coding exon 4 of the MSH6 gene, results from a deletion of one nucleotide at nucleotide position 900, causing a translational frameshift with a predicted alternate stop codon (p.K301Rfs*4). This alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation. |
Myriad Genetics, |
RCV003453839 | SCV004187133 | pathogenic | Lynch syndrome 5 | 2023-08-11 | criteria provided, single submitter | clinical testing | This variant is considered pathogenic. This variant creates a frameshift predicted to result in premature protein truncation. |
Baylor Genetics | RCV003471111 | SCV004195841 | likely pathogenic | Endometrial carcinoma | 2023-01-25 | criteria provided, single submitter | clinical testing |